Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Injection Outcomes in Systemic Lupus Erythematosus
ChiCTR2200066022Phase 4Recruiting
- Sponsor
- Xi'an Jiaotong University
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Xi'an Jiaotong University. Primary endpoint: SELENA-SLEDAI score. Started Nov 2022; status: recruiting.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2200066022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066022.